ALEC241220P2500
- 0.15
- -0.02-11.76%
Alector Newsroom
A Quick Look at Today's Ratings for Alector(ALEC.US), With a Forecast Between $3 to $7
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Poseida PSTX Merger With RHHBY; Alector ALEC Phase 2 Fails
Alector Is Maintained at Buy by BTIG
Morgan Stanley Downgrades Alector to Underweight, Lowers Price Target to $3
Express News | Cantor Fitzgerald Reiterates Overweight on Alector
Alector Analyst Ratings
Alector/AbbVie-Partnered Alzheimer's Drug Disappoints In Mid-Stage Study; Alector Lays Off 17% Of Workforce
Alector Shares May Settle in $2.50-$3.50 Range, Says Mizuho
US Stocks Mixed; Best Buy Posts Downbeat Earnings
Alector Downgraded to Underweight After Disappointing AL002 Phase 2 Results
Leslie's Posts Weak Results, Joins Zoom Video And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Express News | Alector Shares Are Trading Lower After the Company Announced That the INVOKE-2 Phase 2 Clinical Trial Evaluating the Safety and Efficacy of AL002 in Individuals With Early Alzheimer's Disease Failed to Meet Its Primary Endpoint
TD Cowen Maintains Alector(ALEC.US) With Buy Rating
H.C. Wainwright Maintains Alector(ALEC.US) With Buy Rating, Cuts Target Price to $7
Market-Moving News for November 26th
TD Cowen Remains a Buy on Alector (ALEC)
Alector's Strategic Pipeline and Promising PGRN Program Justify Buy Rating Despite AL002 Setback
Alector Price Target Lowered to $7 From $35 at H.C. Wainwright
BTIG Maintains Alector(ALEC.US) With Buy Rating, Cuts Target Price to $5